Updating results

68 results for dyspepsia

Sort: Relevance | Date

Dyspepsia and gastro-oesophageal reflux disease

Everything NICE has said on investigating and managing dyspepsia and gastro-oesophageal reflux disease in an interactive flowchart

NICE Pathway Published September 2014 Last updated October 2019

Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (CG184)

This guideline covers investigating and managing gastro-oesophageal reflux disease (GORD) and dyspepsia in people aged 18 and over. It aims to improve the treatment of GORD and dyspepsia by making detailed recommendations on Helicobacter pylori eradication, and specifying when to consider laparoscopic fundoplication and referral to specialist services.

Clinical guideline Published September 2014 Last updated October 2019

Dyspepsia and gastro‑oesophageal reflux disease in adults (QS96)

This quality standard covers investigating and managing symptoms of dyspepsia (indigestion) and gastro-oesophageal reflux disease (heartburn or reflux) in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

Quality standard Published July 2015

Suspected cancer recognition and referral

Everything NICE has said on suspected cancer, recognition and selection for referral or investigation in primary care in an interactive flowchart

NICE Pathway Published June 2015 Last updated August 2018

Suspected cancer: recognition and referral (NG12)

This guideline covers identifying children, young people and adults with symptoms that could be caused by cancer. It outlines appropriate investigations in primary care, and selection of people to refer for a specialist opinion. It aims to help people understand what to expect if they have symptoms that may suggest cancer.

NICE guideline Published June 2015 Last updated July 2017

Oesophago-gastric cancer (QS176)

This quality standard covers assessing and managing oesophago-gastric cancer in adults. It describes high-quality care in priority areas for improvement.

Quality standard Published December 2018

Head and neck cancer (QS146)

This quality standard covers assessing, diagnosing and managing head and neck cancer, including cancer of the upper aerodigestive tract in people aged 16 and over. It describes high-quality care in priority areas for improvement.

Quality standard Published March 2017

Gastro-oesophageal reflux disease and dyspepsia in adults. Option grid to help people make decisions about long term heartburn treatment

recommended in NICE's guideline on gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management. Editors:...

Published September 2014 Last updated September 2014

Gastro-oesophageal reflux in children and young people (QS112)

This quality standard covers managing symptoms of reflux (regurgitation or bringing up feeds) in babies, children and young people (under 18). It also covers diagnosing and managing gastro-oesophageal reflux disease (also called GORD), which is more severe reflux and heartburn. It describes high-quality care in priority areas for improvement.

Quality standard Published January 2016

Mirabegron for treating symptoms of overactive bladder (TA290)

Evidence-based recommendations on mirabegron (Betmiga) for treating the symptoms of overactive bladder

Technology appraisal guidance Published June 2013

Pirfenidone for treating idiopathic pulmonary fibrosis (TA504)

Evidence-based recommendations on pirfenidone (Esbriet) for idiopathic pulmonary fibrosis (IPF) in adults

Technology appraisal guidance Published February 2018

Irritable bowel syndrome in adults (QS114)

This quality standard covers diagnosing and managing irritable bowel syndrome in adults. It describes high-quality care in priority areas for improvement.

Quality standard Published February 2016

Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)

Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis (MS/RRMS)

Technology appraisal guidance Published August 2014

Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)

Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and preventing recurrent venous thromboembolism

Technology appraisal guidance Published June 2013

Idiopathic pulmonary fibrosis in adults: diagnosis and management (CG163)

This guideline covers diagnosing and managing idiopathic pulmonary fibrosis in people aged 18 and over. It aims to improve the quality of life for people with idiopathic pulmonary fibrosis by helping healthcare professionals to diagnose the condition and provide effective symptom management.

Clinical guideline Published June 2013 Last updated May 2017

Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)

Evidence-based recommendations on rivaroxaban (Xarelto) for preventing adverse outcomes after acute management of acute coronary syndrome (ACS)

Technology appraisal guidance Published March 2015

Infliximab for acute exacerbations of ulcerative colitis (TA163)

Evidence-based recommendations on infliximab (Remicade) for acute exacerbations of ulcerative colitis in adults

Technology appraisal guidance Published December 2008

What specialist investigations should be conducted to exclude a diagnosis of functional dyspepsia in people with uninvestigated dyspepsia that does not respond to PPIs or H 2   receptor antagonists (H 2 RAs) despite optimum primary care?

be conducted to exclude a diagnosis of functional dyspepsia in people with uninvestigated dyspepsia that does not respond...

Research recommendation Published November 2019

Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (TA249)

Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in atrial fibrillation (AF)

Technology appraisal guidance Published March 2012

Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B (TA96)

Evidence-based recommendations on adefovir dipivoxil (Hepsera) and peginterferon alfa-2a (Pegasys) for the treatment of chronic hepatitis B

Technology appraisal guidance Published February 2006

Non-Hodgkin's lymphoma: diagnosis and management (NG52)

This guideline covers diagnosing and managing non-Hodgkin's lymphoma in people aged 16 years and over. It aims to improve care for people with non-Hodgkin's lymphoma by promoting the best tests for diagnosis and staging and the most effective treatments for 6 of the subtypes. Tests and treatments covered include excision biopsy, radiotherapy, immunochemotherapy and stem cell transplantation.

NICE guideline Published July 2016

Laparoscopic insertion of a magnetic titanium ring for gastro-oesophageal reflux disease (IPG585)

Evidence-based recommendations on laparoscopic insertion of a magnetic titanium ring for gastro-oesophageal reflux disease (GORD) in adults

Interventional procedures guidance Published July 2017

Myocardial infarction: cardiac rehabilitation and prevention of further cardiovascular disease (CG172)

This guideline covers cardiac rehabilitation and preventing further cardiovascular disease in people aged 18 and over who have had a myocardial infarction. It aims to promote the health of people who have had an MI by encouraging them to attend a cardiac rehabilitation programme and advising them on a healthy lifestyle. It also includes advice on drug therapy.

Clinical guideline Published November 2013

Generalised anxiety disorder: quetiapine (ESUOM12)

Summary of the evidence on quetiapine monotherapy for treating generalised anxiety disorder (GAD) to inform local NHS planning and decision-making

Evidence summary Published May 2013

Patisiran for treating hereditary transthyretin amyloidosis (HST10)

Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy

Highly specialised technologies guidance Published August 2019

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA327)

Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treatment and secondary prevention of deep vein thrombosis (DVT) or pulmonary embolism

Technology appraisal guidance Published December 2014

Transient ischaemic attack: clopidogrel (ESUOM23)

Summary of the evidence on clopidogrel for treating transient ischaemic attack (TIA) to inform local NHS planning and decision-making

Evidence summary Published December 2013

Bile acid malabsorption: colesevelam (ESUOM22)

Summary of the evidence on colesevelam for treating bile acid malabsorption (BAM) to inform local NHS planning and decision-making

Evidence summary Published October 2013

Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)

This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in the 48 hours after onset of symptoms.

NICE guideline Published May 2019

Orthostatic hypotension due to autonomic dysfunction: midodrine (ESNM61)

Summary of the evidence on midodrine for orthostatic hypotension due to autonomic dysfunction to inform local NHS planning and decision-making

Evidence summary Published October 2015

Type 2 diabetes: insulin degludec/liraglutide (Xultophy) (ESNM60)

Summary of the evidence on insulin degludec/liraglutide (Xultophy) for treating type 2 diabetes to inform local NHS planning and decision-making

Evidence summary Published July 2015

Irritable bowel syndrome in adults: diagnosis and management (CG61)

This guideline covers diagnosing and managing irritable bowel syndrome (IBS) in people aged 18 and over. It details how to accurately diagnose IBS, and aims to improve the quality of life for adults with IBS by promoting effective management using dietary and lifestyle advice, pharmacological therapy and referral for psychological interventions.

Clinical guideline Published February 2008 Last updated April 2017

In people who experience symptoms of gastro-oesophageal reflux disease (GORD) or symptoms suggestive of GORD, what patient characteristics, risk factors and predictors indicate when endoscopy is needed to exclude Barrett's oesophagus?

details Comes from guidance Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Number CG184 Date

Research recommendation Published November 2019

What is the effectiveness of laparoscopic fundoplication compared with medical management in people with GORD that does not respond to optimal proton pump inhibitor (PPI) treatment?

details Comes from guidance Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Number CG184 Date

Research recommendation Published November 2019

Laparoscopic fundoplication compared with medical management:- What is the effectiveness of laparoscopic fundoplication compared with medical management in people with GORD that does not respond to optimal proton pump inhibitor (PPI) treatment?

details Comes from guidance Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Number CG184 Date

Research recommendation Published June 2015

What specialist management is effective for people whose symptoms do not respond to PPIs despite optimum primary care, or for people whose symptoms return after surgery?

details Comes from guidance Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Number CG184 Date

Research recommendation Published November 2019

Other specialist management:- What specialist management is effective for people whose symptoms do not respond to PPIs despite optimum primary care, or for people whose symptoms return after surgery?

details Comes from guidance Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Number CG184 Date

Research recommendation Published June 2015

What is the clinical effectiveness of double-dose PPIs in people with severe erosive reflux disease (Los Angeles classification grade C/D or Savary–Miller grade 3/4): to reduce severe oesophagitis to control symptoms as maintenance therapy?

details Comes from guidance Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Number CG184 Date

Research recommendation Published November 2019

Dyspepsia: Management of dyspepsia in adults in primary care (CG17)

This guidance has been updated and replaced by NICE guideline CG184.

Clinical guideline Published August 2004

Past appeals and decisions

collagenase clostridium histolyticum 30 November 2015 TA007 Dyspepsia - proton pump inhibitors 29 June 2000 TA059 Electroconvulsive

Published May 2019 Last updated May 2019

Gastroparesis in adults: oral erythromycin (ESUOM13)

Summary of the evidence on oral erythromycin for gastroparesis (delayed stomach emptying) in adults to inform local NHS planning and decision-making

Evidence summary Published June 2013

Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)

Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making

Evidence summary Published March 2016

Schizophrenia: omega-3 fatty acid medicines (ESUOM19)

Summary of the evidence on omega-3 fatty acid medicines for treating schizophrenia to inform local NHS planning and decision-making

Evidence summary Published September 2013

Dementia. Enteral (tube) feeding for people living with severe dementia (patient decision aid)

there are treatable reasons for the person's loss of appetite (such as indigestion, constipation or a sore mouth) these should be...

Published June 2018 Last updated June 2018

Cerebral palsy in under 25s: assessment and management (NG62)

This guideline covers diagnosing, assessing and managing cerebral palsy in children and young people from birth up to their 25th birthday. It aims to make sure they get the care and treatment they need for the developmental and clinical comorbidities associated with cerebral palsy, so that they can be as active and independent as possible.

NICE guideline Published January 2017

Cystic fibrosis: long-term azithromycin (ESUOM37)

Summary of the evidence on long-term azithromycinoral for treating cystic fibrosis (CF) to inform local NHS planning and decision-making

Evidence summary Published November 2014